echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nature's major research: bid farewell to waist wear!

    Nature's major research: bid farewell to waist wear!

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neurodegenerative diseases can cause the weakness of nerve cells to continue to degenerate or die, as well as a series of problems in thinking, attention and memory


    Currently, there are approximately 850,000 dementia patients in the UK, which is expected to increase to 1.


    prevention

    The biomarkers currently used to identify neurodegenerative diseases are extracted from lumbar puncture cerebrospinal fluid (CSF)


    A core and irreversible feature of many neurodegenerative diseases is damage to nerve fibers, which leads to the release of a protein called neurofilament light chain (NfL) in the blood


    diagnosis

    Recently, a new study of more than 3,000 people conducted by a team of King’s College London (KCL) and Lund University (Lund) showed for the first time that NfL levels can accurately indicate that people with cognitive problems have potential neurodegeneration.


    NfL levels can accurately indicate the presence of underlying neurodegeneration in people with cognitive problems, such as Down’s syndrome dementia, motor neuron disease (ALS), and frontotemporal dementia


    The study examined 3138 samples, including people without cognitive impairment, people with neurodegenerative diseases, people with Down syndrome, and people with depression


    Compared with people without cognitive problems, all patients with neurodegenerative diseases have higher levels of NfL in the blood.


    Plasma neurofilament (NfL) in different diagnostic groups of KCL and Lund .


    Plasma neurofilament (NfL) in different diagnostic groups of KCL and Lund .


    Although blood-based NfL cannot distinguish all diseases, it can provide insight into different groups in certain diseases


    In the sample from King’s College London, these age-related cut-off points are 90% accurate in highlighting neurodegeneration in people over 65, and 100% accurate in detecting motor neuron diseases and Down’s syndrome dementia Sex, there are very similar results in Lund’s sample


    NfL can distinguish patients with depression from patients with neurodegenerative diseases, the latter usually manifested as primary mental disorders in the early stages of disease development, such as frontotemporal dementia


    The performance of plasma neurofilament (NfL) in identifying neurodegenerative diseases, the control group (CU and SCD)> 65 years old (A), the control group (CU and SCD) <65 years old (B) and depression (C)

    The performance of plasma neurofilament (NfL) in identifying neurodegenerative diseases, the control group (CU and SCD)> 65 years old (A), the control group (CU and SCD) <65 years old (B) and depression (C)

    This study shows that in adults with Down syndrome who are genetically predisposed to Alzheimer's disease, neurofilament chain levels are particularly high


    In adults with Down syndrome who are genetically predisposed to Alzheimer's disease, the level of neurofilament chain is particularly high


    This new marker may be used to improve the diagnosis of Alzheimer's disease in patients with Down syndrome and as a biomarker to show whether the treatment is effective


    NfL is a promising biomarker that can speed up the diagnosis of neurodegenerative diseases and shorten clinical trials.
    NfL is a promising biomarker that can speed up the diagnosis of neurodegenerative diseases and shorten clinical trials.

    Co-senior author of the study, from King's College London and South London and Maudsley NHS Foundation Abdul Dr.
    Hye NIHR Biomedical Research Center of the Maudsley Trust, said: "We show for the first time in a number of diseases, a Biomarkers can very accurately indicate the existence of underlying neurodegeneration
    .
    Although it is not specific for any kind of disease, it can help services such as memory clinics as a quick screening tool to identify memory, thinking or mental problems Whether it is the result of neurodegeneration
    .

    Fund screening

    At the same time, Dr.
    Hye also pointed out that blood-based NfL provides a scalable and widely used alternative to invasive and expensive tests for dementia
    .
    In some European countries, such as Sweden or the Netherlands, it has been used as a routine assessment, and our age-related demarcation line can provide clinicians with a benchmark and quick test to indicate those who exhibit problems with thinking and memory Human neurodegeneration
    .

    Co-senior author, Professor Oskar Hansson of Lund University, said: "Blood testing has great potential in improving the diagnosis of dementia in specialized memory clinics and primary care
    .
    Plasma NfL is very useful in many clinical situations and can be useful for doctors.
    Provide a lot of information, as this large-scale research shows'
    .

    Lead author Dr.
    Nicholas Ashton of King’s College London concluded: "We are entering an exciting period of blood tests like plasma NfL combined with other emerging blood biomarkers such as phosphorylated tau (p-tau).
    , Is beginning to give us a meaningful and non-invasive insight into brain diseases
    .

    Original source:

    A multicentre validation study of the diagnostic value of plasma neurofilament light.
    DOI: 10.
    1038/s41467-021-23620-z

    10.
    1038/s41467-021-23620-z

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.